seventeen consecutively admitted poor risk acute myeloid leukaemia ( aml ) patients and 4 patients with myelodysplastic syndrome ( mds ) were treated with a remission-induction regimen consisting of a 7-day continuous intravenous infusion of conventional doses of cytarabine and of three 24-h constant rate infusions of daunorubicin administered intermittently on days 1 , 3 and 5 .
C0023467
acute myeloid leukaemia
C0011015
daunorubicin